| Literature DB >> 24343531 |
Gang Du1, Hui Tu, Xiaojing Li, Aijie Pei, Jing Chen, Zhigang Miao, Jizhen Li, Chen Wang, Hong Xie, Xingshun Xu, Heqing Zhao.
Abstract
Daphnetin (DAP), a coumarin derivative, has been reported to have multiple pharmacological actions including analgesia, antimalarial, anti-arthritic, and anti-pyretic properties. It is unclear whether DAP has neuroprotective effects on ischemic brain injury. In this study, we found that DAP treatment (i.c.v.) reduced the infarct volume at 24 h after ischemia/reperfusion injury and improved neurological behaviors in a middle cerebral artery occlusion mouse model. Moreover, we provided evidences that DAP had protective effects on infarct volume in neonate rats even it was administrated at 4 h after cerebral hypoxia/ischemia injury. To explore its neuroprotective mechanisms of DAP, we examined the protection of DAP on glutamate toxicity-induced cell death in hippocampal HT-22 cells. Our results demonstrated that DAP protected against glutamate toxicity in HT-22 cells in a concentration-dependent manner. Further, we found that DAP maintained the cellular levels of glutathione and superoxide dismutase activity, suggesting the anti-oxidatant activity of DAP. Since DAP has been used for the treatment of coagulation disorder and rheumatoid arthritis for long time with a safety profile, DAP will be a promising agent for the treatment of stroke.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24343531 DOI: 10.1007/s11064-013-1218-6
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996